STAA Surges More Than 20%, Is It Still a Good Buy Now?

TradingKey - After the market close on April 8, 2026, STAAR Surgical ( STAA) released a surprise preliminary earnings report: first-quarter 2026 net sales are expected to exceed $90 million, more than doubling the $42.6 million recorded in the same period of 2025. This guidance significantly beat the $67.6 million consensus estimate from analysts surveyed by FactSet. After the opening bell on April 9, STAA shares surged more than 25% intraday before eventually closing near $25.21. Just one month ago, the company had released its full-year 2025 financial report, which showed a 23.7% decline in annual net sales and a net loss of $80.4 million—this Q1 guidance has effectively transformed the 'earnings inflection point' from market expectation into data-backed reality. 

I. What does STAA do?

STAAR Surgical is a California-based ophthalmic medical device company whose flagship product is the EVO Implantable Collamer Lens (ICL). Unlike standard soft contact lenses, the ICL is an intraocular lens implanted through minimally invasive surgery to permanently correct vision, making it especially suitable for individuals with corneas that are too thin or prescriptions that are too high for laser eye surgery. STAAR maintains a dominant position in the global ICL market; as of February 2026, cumulative global implants have surpassed 4 million units. In the U.S. high-myopia segment (above -8.0D), the EVO ICL holds a 72% market share, while in China's phakic intraocular lens (PIOL) market, STAAR similarly commands approximately a 95% share. According to a report by FMI, the global ICL market is projected to expand at a compound annual growth rate (CAGR) of 13.1%.

II. Why was doubling growth achieved?

The completion of inventory destocking in the Chinese market is the primary driver. In the first quarter of 2025, STAAR nearly suspended shipments to Chinese distributors due to excessively high inventory backlogs. By the end of the first quarter of 2026, inventory levels had returned to normal ranges and supply fully resumed. Furthermore, the next-generation EVO+ ICL (V5) was officially launched in China in January 2026, featuring a larger optical zone and superior night vision quality, while adopting a premium pricing strategy to target the high-end market. In the U.S. market, the FDA has approved an age extension for EVO ICL to 21-60 years, adding approximately 8 million potential patients to the U.S. market. The convergence of these multiple factors has collectively driven a significant turnaround in performance.

III. How did STAA achieve its turnaround?

2025 was a trough year for STAA: distributor inventories were elevated, shipments to China nearly ground to a halt, the merger with Alcon failed (shareholder approval was not obtained), and the CEO along with several senior executives departed. Full-year net sales were $239.4 million, down 23.7% year-over-year, with a net loss of $80.4 million—a sharp deterioration from the previous year's net profit of $21.3 million. However, preliminary recovery signals emerged in the fourth quarter of 2025: Q4 net sales reached $57.8 million, up 18.1% year-over-year, with gross margin improving to 75.7%. During the earnings call in early March, management defined 2026 as a "true inflection point year," and the Q1 guidance in early April, projecting over 100% growth, fully validated this inflection point.

IV. Did Short Covering Magnify STAA's Single-Day Gain?

Beyond the turnaround in fundamentals, STAA's single-day rally was significantly fueled by short covering. After a year of persistent share price declines that led to a buildup of heavy short interest, the sudden release of better-than-expected Q1 guidance sent shares higher, forcing short sellers to scramble to cover their positions. This passive buying further magnified the single-day advance.

V. What competition does STAA face?

STAAR is not without competition. In the Chinese market, Eyebright Medical's domestic PIOL product 'Crystal' was approved for marketing in January 2025 and is expected to capture approximately 14% of the Chinese PIOL market share by 2034. However, STAAR's products have already upgraded to the V5 generation, and its first-mover advantage and technical barriers are difficult to overcome in the short term. On April 9, several institutions raised their ratings and price targets: Canaccord Genuity upgraded the rating from 'Hold' to 'Buy' and raised its price target from $22 to $27; Wedbush raised its price target from $21 to $26 while maintaining a Neutral rating.

VI. Conclusion

The essence of STAA's recent rally is a key validation of the "turnaround" thesis, and the official Q1 earnings report in early May will be the next milestone to determine if this recovery is sustainable. As the global leader in the ICL market, STAAR is regaining growth momentum from its trough, leveraging its near-monopoly share in China and dominance in the U.S. high myopia market, alongside catalysts such as inventory recovery and new product launches.